Overview
Allakos Inc. is a biopharmaceutical company based in the United States, specifically in Redwood City, California. It operates within the healthcare sector, focusing primarily on developing innovative therapeutics for allergic, inflammatory, and proliferative diseases. A key aspect of Allakos Inc.’s portfolio includes the development of monoclonal antibodies targeting siglec-8, an immune system receptor involved in the regulation of eosinophil and mast cell functions. These cells play crucial roles in the pathology of various diseases. The company’s most notable project includes the investigation of antolimab (AK002), their lead antibody, for conditions like eosinophilic gastritis, eosinophilic gastroenteritis, and other related disorders. Allakos Inc. is dedicated to addressing unmet medical needs in diseases associated with an overactive immune response.
Basic Stats
The share price of Allakos Inc. as of May 14, 2025 is $0.33 / share.
The Factor Analysis chart (below right) shows a view of Allakos Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | |
| Earnings Date | |
| EPS (TTM) | |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | 1.34 |
| Beta | -1.40 |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | |
| ROE | |
| ROIC | |
| CROIC | |
| OCROIC | |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | |
| Profitability | |
| Quality Score | |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Allakos Inc. is $1.26. The forecasts range from a low of $0.30 to a high of $3.15. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Allakos Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2022-09-12 | Cantor Fitzgerald | Overweight | Maintains | |
| 2022-05-24 | Goldman Sachs | Neutral | Maintains | |
| 2022-05-12 | SVB Leerink | Market Perform | Maintains | |
| 2022-05-11 | Barclays | Underweight | Maintains | |
| 2022-05-10 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-02-16 | SVB Leerink | Market Perform | Maintains | |
| 2021-12-28 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-12-23 | Morgan Stanley | Equal-Weight | Maintains | |
| 2021-12-23 | Goldman Sachs | Neutral | Maintains | |
| 2021-12-22 | William Blair | Outperform | Market Perform | Downgrade |
| 2021-12-22 | SVB Leerink | Outperform | Market Perform | Downgrade |
| 2021-12-22 | Jefferies | Buy | Hold | Downgrade |
| 2021-12-22 | Cowen & Co. | Outperform | Market Perform | Downgrade |
| 2021-12-22 | Barclays | Underweight | Maintains | |
| 2021-12-13 | B of A Securities | Buy | Maintains | |
| 2021-11-10 | Morgan Stanley | Equal-Weight | Maintains | |
| 2021-08-26 | Morgan Stanley | Equal-Weight | Initiate | |
| 2021-07-15 | Cowen & Co. | Outperform | Initiate | |
| 2021-05-18 | HC Wainwright & Co. | Buy | Initiate | |
| 2021-01-15 | B of A Securities | Buy | Initiate | |
| 2020-12-21 | SVB Leerink | Outperform | Initiate | |
| 2018-08-13 | William Blair | Outperform | Initiate | |
| 2018-08-13 | Goldman Sachs | Neutral | Initiate | |
| 2023-01-27 | Morgan Stanley | Equal-Weight | Maintains | |
| 2023-02-27 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2023-03-07 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2023-03-07 | Piper Sandler | Overweight | Initiate | |
| 2023-05-12 | Jefferies | Hold | Buy | Upgrade |
| 2023-09-27 | JMP Securities | Market Outperform | Initiate | |
| 2023-12-18 | William Blair | Market Perform | Outperform | Upgrade |
| 2023-11-14 | Barclays | Underweight | Underweight | Maintains |
| 2023-11-14 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2023-11-28 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2024-01-17 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2024-01-17 | Barclays | Underweight | Underweight | Maintains |
| 2024-01-17 | Jefferies | Buy | Hold | Downgrade |
| 2024-06-26 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2024-06-20 | Cantor Fitzgerald | Neutral | Reiterate | |
| 2024-07-18 | Jefferies | Hold | Hold | Maintains |
| 2024-09-26 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
